FDA & Peptide Compliance Consulting

FDA & Peptide Regulatory Compliance Consulting — Mahadev Mukherjee
Mahadev Mukherjee — Grow With Mahadev
FILE REF: FDA-PEP-2026 · REV. AUG 2026
Regulatory Compliance Consulting

FDA and peptide compliance, read the way a regulator reads it.

I help peptide brands, research chemical suppliers, and biotech operators stay ahead of FDA classification shifts and PCAC votes — before a compliance gap becomes a shut-down merchant account.

18 Years in Pharma & Biotech
#1 US Google Ranking — Peptide Compliance Content
12 Peptides Reclassified, Apr 2026 — Tracked in Full

Why work with me

Authority
Published Research
Asian Journal of Pharmaceutical Research & Development, October 2025. ORCID-verified researcher (0009-0009-6433-5073).
Author
“The 2026 US Peptide Compliance and Research Dossier” — the reference I wrote covering FDA Category 2 reclassifications, PCAC voting patterns, and compliant marketing language for the peptide research industry.
Current Role
Lead compliance consultant for Profound Aminos — built 60+ FDA/FTC/Google-compliant peptide research reference documents, several holding #1 US Google rankings.
Track Record
18 years in pharmaceutical operations and management, 12 of them in gynecology, IVF, and reproductive medicine. Direct client work advising US peptide and research chemical brands on FDA/FTC-facing content.

What I help with

Scope of work
01

Compliance Audits

FDA/FTC audits on peptide and research chemical marketing, product claims, and site copy — before a regulator or a payment processor flags it for you.

02

Classification Strategy

Guidance through Category 1 / Category 2 peptide classifications and PCAC decisions, tracked as they move rather than reacted to after the fact.

03

Market Entry Content Review

Compliant messaging and content review for peptide brands entering or scaling in the US market, so growth doesn’t outrun the regulatory line.

04

Standing Regulatory Monitoring

Ongoing tracking of FDA and PCAC movement on the compounds relevant to your catalog, delivered as plain, decision-ready notes — not a legal memo.

Current classification docket

As tracked, Aug 2026
Compound Status
BPC-157, TB-500, KPV, MOTS-c, Emideltide, Semax Removed from Cat. 2, Apr 2026 Cleared
Epitalon, LL-37, Dihexa, GHK-Cu, PEG-MGF, Melanotan II Removed from Cat. 2, Apr 2026 Cleared
CJC-1295, Ipamorelin Negative PCAC votes · not on Jul 23–24 2026 agenda Regulatory Gap
This snapshot moves with each PCAC session. Brands operating on a stale classification are the ones that lose their merchant accounts — I track this so you don’t have to.

Proof of work

Verify independently
The Dossier
“The 2026 US Peptide Compliance and Research Dossier” — Gumroad, $197. Also available as a Kindle edition.
Upwork
5-star rated on Upwork for pharma and medical consulting work — view profile.
ORCID
Verified researcher record — 0009-0009-6433-5073.
Search Ranking
Independent peptide compliance content holds the #1 Google ranking in the US for its topic — search it yourself before you take my word for it.

Bring me your catalog before your next PCAC surprise does.

Tell me about your business challenge. I personally review every submission and respond within 24 hours with a clear, actionable direction — no sales pitch, no generic advice.

Book Your Free AI Audit Call